Moreover, by combining two negative biomarkers, FoxP3 (Tregs) and CD68 (TAMs), we can select an even more specific group of patients who benefited from treatment with PD-1 inhibitors the most, and in the melanoma subgroup, we confirmed its predictive value but not prognostic. This evidence concerns the gene FOXP3 and melanoma.